24/7 Market News Snapshot 22 September, 2025 – Onconetix, Inc. Common Stock (NASDAQ:ONCO)
DENVER, Colo., 22 September, 2025 (www.247marketnews.com) – (Nasdaq:ONCO) are discussed in this article.
Onconetix, Inc. (Nasdaq:ONCO), a leading biotechnology firm specializing in advanced solutions for men’s health and oncology, has seen a notable increase in pre-market trading, with shares rising to $3.283, reflecting a surge of 10.54% from the previous close of $2.970. This uptick, marked by an impressive trading volume of 538.08K shares, signals strong market interest and investor confidence, particularly following a significant licensing agreement with Immunovia AB.
Under this strategic partnership, which involves Onconetix’s wholly-owned subsidiary, Proteomedix AG, Immunovia is set to receive master cells vital for producing antibodies associated with key biomarkers in its innovative pancreatic cancer diagnostic test, PancreaSure. The agreement also encompasses a license for critical intellectual property necessary for manufacturing reagents essential for measuring these biomarkers. Through this collaboration, Immunovia aims to enhance operational efficiency by sourcing these important reagents directly from Proteomedix.
As part of the agreement, Immunovia will invest $700,000 to Proteomedix over the years 2025 and 2026, alongside a 3% royalty on net sales from PancreaSure and related products derived from the licensed intellectual property between 2026 and 2032.
Beat Rheiner, PhD, CEO of Proteomedix, expressed enthusiasm about the partnership, emphasizing the significance of early pancreatic cancer detection as a means to improve patient outcomes. Karina Fedasz, Interim CEO of Onconetix, reaffirmed the company’s dedication to innovation and expanding its offerings, notably the early prostate cancer detection test, Proclarix®. This agreement illustrates Onconetix’s commitment to delivering pioneering healthcare solutions, poised to drive advancements in cancer diagnostics and improve overall patient care.